Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Knop

Showing results (401-410 of 455) with videos related to

Pageof 46
Sort By:
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
Gastro Hep Advances|August 12, 2024
Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid MalabsorptionMartin L Kårhus, David P Sonne, Martin Thomasen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2019
<i>N</i>-acyl taurines are endogenous lipid messengers that improve glucose homeostasisTrisha J Grevengoed, Samuel A J Trammell, Michele K McKinney, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
European Journal of Endocrinology|April 16, 2025
High-intensity interval training improves insulin sensitivity in individuals with prediabetesPernille Mensberg, Clarissa Frandsen, Christian S Carl, et al.
Diabetes, Obesity & Metabolism|February 13, 2023
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motilityHenriette H Nerild, Andreas Brønden, Ida M Gether, et al.
Eclinicalmedicine|March 2, 2026
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trialCasper K Nielsen, Thorir G Pálsson, Julie L Forman, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover StudyIda M Gether, Vivian Kliim-Hansen, Petur T Olafsson, et al.
Journal of Clinical Medicine|October 10, 2020
One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled TrialLouise Vedtofte, Emilie Bahne, Signe Foghsgaard, et al.
Diabetes, Obesity & Metabolism|October 6, 2025
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trialDavid S Mathiesen, Josefine V Hansen, Aske Høck, et al.
Pageof 46

Showing results (401-410 of 455) with videos related to

Sort By:
Pageof 46
Diabetes, Obesity & Metabolism|October 10, 2025
Acute effects of GIP and GLP-1 receptor antagonism in totally pancreatectomized individuals: A randomized double-blind, placebo-controlled crossover studyLiva S L Krogh, Mads M Helsted, Anders Englund, et al.
Gastro Hep Advances|August 12, 2024
Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid MalabsorptionMartin L Kårhus, David P Sonne, Martin Thomasen, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 20, 2019
<i>N</i>-acyl taurines are endogenous lipid messengers that improve glucose homeostasisTrisha J Grevengoed, Samuel A J Trammell, Michele K McKinney, et al.
The Lancet. Diabetes & Endocrinology|May 22, 2026
Effects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trialMads M Helsted, Christiane Fonnesbech-Wulff, Nina L Schaltz, et al.
European Journal of Endocrinology|April 16, 2025
High-intensity interval training improves insulin sensitivity in individuals with prediabetesPernille Mensberg, Clarissa Frandsen, Christian S Carl, et al.
Diabetes, Obesity & Metabolism|February 13, 2023
Liraglutide changes postprandial responses of gut hormones involved in the regulation of gallbladder motilityHenriette H Nerild, Andreas Brønden, Ida M Gether, et al.
Eclinicalmedicine|March 2, 2026
Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trialCasper K Nielsen, Thorir G Pálsson, Julie L Forman, et al.
Diabetes, Obesity & Metabolism|March 10, 2026
Intravenous Oxytocin Has no Effect on Ad Libitum Food Intake or Postprandial Plasma Glucose Concentrations in Individuals With Obesity: A Randomised, Placebo-Controlled, Double-Blind, Crossover StudyIda M Gether, Vivian Kliim-Hansen, Petur T Olafsson, et al.
Journal of Clinical Medicine|October 10, 2020
One Year's Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled TrialLouise Vedtofte, Emilie Bahne, Signe Foghsgaard, et al.
Diabetes, Obesity & Metabolism|October 6, 2025
Repurposing colchicine for reduction of residual inflammatory risk in type 1 diabetes: Design and rationale of the REC1TE trialDavid S Mathiesen, Josefine V Hansen, Aske Høck, et al.
Pageof 46